Sort by:
Need a comprehensive medical report on "Acute Myeloid Leukemia (AML)"?
Analyze the latest clinical research and treatment options
Summarize scientific findings from medical journals
A Study of ASP2215 (Gilteritinib), Administered as Maintenance Therapy Following Induction/Consolidation Therapy for Subjects With FMS-like Tyrosine Kinase 3 (FLT3/ITD) Acute Myeloid Leukemia (AML) in First Complete Remission
Phase 2
Completed
- Conditions
- Acute Myeloid Leukemia (AML)Acute Myeloid Leukemia With FMS-like Tyrosine Kinase (FLT3) / Internal Tandem Duplication (ITD) Mutation
- Interventions
- Drug: Placebo
- First Posted Date
- 2016-10-07
- Last Posted Date
- 2024-11-26
- Lead Sponsor
- Astellas Pharma Global Development, Inc.
- Target Recruit Count
- 98
- Registration Number
- NCT02927262
- Locations
- 🇺🇸
Site US10017, Gainesville, Florida, United States
🇺🇸Site US10030, Jacksonville, Florida, United States
🇺🇸Site US10012, Chicago, Illinois, United States
Leukemia Stem Cell Detection in Acute Myeloid Leukemia
Phase 3
Terminated
- Conditions
- Acute Myeloid Leukemia (AML)
- Interventions
- Procedure: Allogeneic HCTDrug: Consolidation chemotherapy
- First Posted Date
- 2016-10-07
- Last Posted Date
- 2022-04-21
- Lead Sponsor
- Wake Forest University Health Sciences
- Target Recruit Count
- 18
- Registration Number
- NCT02927938
- Locations
- 🇺🇸
Levine Cancer Institute, Charlotte, North Carolina, United States
A Study Evaluating the Safety and Pharmacology of Atezolizumab Administered in Combination With Immunomodulatory Agents in Participants With Acute Myeloid Leukemia (AML)
- First Posted Date
- 2016-09-08
- Last Posted Date
- 2020-03-13
- Lead Sponsor
- Hoffmann-La Roche
- Target Recruit Count
- 40
- Registration Number
- NCT02892318
- Locations
- 🇺🇸
City of Hope, Duarte, California, United States
🇺🇸Yale University, New Haven, Connecticut, United States
🇺🇸The NewYork-Presbyterian Hospital Columbia University Medical Center, New York, New York, United States
A Study to Evaluate Escalating Doses of ASP1235 (AGS62P1) Given as Monotherapy in Subjects With Acute Myeloid Leukemia (AML)
- First Posted Date
- 2016-08-12
- Last Posted Date
- 2024-10-23
- Lead Sponsor
- Astellas Pharma Global Development, Inc.
- Target Recruit Count
- 43
- Registration Number
- NCT02864290
- Locations
- 🇺🇸
Site US00006, Duarte, California, United States
🇺🇸Site US00003, Baltimore, Maryland, United States
🇺🇸Site US00007, Boston, Massachusetts, United States
Reflexology: An Intervention for Acute Myeloid Leukemia(AML) Patients
Not Applicable
- Conditions
- Acute Myeloid Leukemia
- First Posted Date
- 2016-08-11
- Last Posted Date
- 2017-02-15
- Lead Sponsor
- Rambam Health Care Campus
- Target Recruit Count
- 50
- Registration Number
- NCT02863302
- Locations
- 🇮🇱
Rambam Health Care Campus, Haifa, Israel
Study of Quizartinib in Japanese Patients With Newly Diagnosed Acute Myeloid Leukemia (AML)
Phase 1
Completed
- Conditions
- Acute Myeloid Leukemia
- Interventions
- First Posted Date
- 2016-07-15
- Last Posted Date
- 2025-03-05
- Lead Sponsor
- Daiichi Sankyo Co., Ltd.
- Target Recruit Count
- 7
- Registration Number
- NCT02834390
Dose-Escalation Study of Ponatinib, a FLT3 Inhibitor, With and Without Combination of 5-Azacytidine, in Patients With FLT3-Mutated Acute Myeloid Leukemia (AML)
Phase 1
Withdrawn
- Conditions
- LeukemiaFLT3-Mutated High-Risk Myelodysplastic SyndromeFLT3-Mutated Acute Myeloid Leukemia
- Interventions
- First Posted Date
- 2016-07-12
- Last Posted Date
- 2017-06-02
- Lead Sponsor
- M.D. Anderson Cancer Center
- Registration Number
- NCT02829840
A Dose Finding Study of IDH305 With Standard of Care in IDH1 Mutant Acute Myeloid Leukemia
- First Posted Date
- 2016-07-11
- Last Posted Date
- 2019-04-10
- Lead Sponsor
- Novartis Pharmaceuticals
- Registration Number
- NCT02826642
Provision of TCRγδ T Cells and Memory T Cells Plus Selected Use of Blinatumomab in Naïve T-cell Depleted Haploidentical Donor Hematopoietic Cell Transplantation for Hematologic Malignancies Relapsed or Refractory Despite Prior Transplantation
Phase 2
Active, not recruiting
- Conditions
- Myeloid SarcomaChronic Myeloid Leukemia (CML)Myelodysplastic Syndrome (MDS)Acute Lymphoblastic Leukemia (ALL)Acute Myeloid Leukemia (AML)Non-Hodgkin Lymphoma (NHL)Juvenile Myelomonocytic Leukemia (JMML)
- Interventions
- First Posted Date
- 2016-06-06
- Last Posted Date
- 2025-08-12
- Lead Sponsor
- St. Jude Children's Research Hospital
- Target Recruit Count
- 170
- Registration Number
- NCT02790515
- Locations
- 🇺🇸
St. Jude Children's Research Hospital, Memphis, Tennessee, United States
Clinical Trial of BP1001 in Combination With With Venetoclax Plus Decitabine in AML
Phase 2
Recruiting
- Conditions
- Acute Myeloid Leukemia (AML)
- Interventions
- Drug: BP1001 in combination with Ventoclax plus decitabine
- First Posted Date
- 2016-05-25
- Last Posted Date
- 2025-03-07
- Lead Sponsor
- Bio-Path Holdings, Inc.
- Target Recruit Count
- 108
- Registration Number
- NCT02781883
- Locations
- 🇺🇸
UCLA Medical Center, Los Angeles, California, United States
🇺🇸Georgia Cancer Center at Augusta University, Augusta, Georgia, United States
🇺🇸University of Kansas Cancer Center, Fairway, Kansas, United States